NVO

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Peers: LLY AZN MRK PFE ABBV JNJ NVS BMY SNY AMGN

| Held by: PVAL AVDE PPH WCMI PINK PID AQEC APIE CNEQ AVIV

Index	-
Market Cap	162.32B
Enterprise Value	181.56B
Income	18.95B
Sales	50.91B
Book/sh	7.05
Cash/sh	0.99
Dividend Est.	1.80 (3.73%)
Dividend TTM	1.80 (3.73%)
Dividend Ex-Date	Mar 30, 2026
Dividend Gr. 3/5Y	26.98% 19.93%
Payout	36.87%
Employees	68794
IPO	Apr 30, 1981

P/E	11.34
Forward P/E	14.68
PEG	-
P/S	3.19
P/B	6.86
P/C	48.68
P/FCF	25.30
EV/EBITDA	6.85
EV/Sales	3.57
Quick Ratio	0.56
Current Ratio	0.79
Debt/Eq	0.72
LT Debt/Eq	0.59
Option/Short	Yes / Yes

EPS (ttm)	4.26
EPS next Y	3.29
EPS next Q	0.80
EPS this Y	-9.42%
EPS next Y	-0.07%
EPS next 5Y	-0.79%
EPS past 3/5Y	26.28% 20.36%
Sales past 3/5Y	23.19% 19.21%
EPS Y/Y TTM	26.24%
Sales Y/Y TTM	16.79%
EPS Q/Q	86.54%
Sales Q/Q	37.63%
Earnings	May 06 BMO
EPS/Sales Surpr.	18.04% 1.50%

Insider Own	0.00%
Insider Trans	-
Inst Own	9.79%
Inst Trans	-3.12%
ROA	24.14%
ROE	73.79%
ROIC	38.15%
Gross Margin	81.84%
Oper. Margin	45.45%
Profit Margin	37.23%
SMA20	8.81%
SMA50	10.00%
SMA200	0.88%
Trades

Shs Outstand	3.37B
Shs Float	3.36B
Short Float	0.73%
Short Ratio	1.60
Short Interest	24.48M
52W High	71.79 -32.67%
52W Low	35.12 37.64%
Volatility	2.09% 3.00%
ATR (14)	1.37
RSI (14)	68.51
Beta	0.77
Rel Volume	0.54
Avg Volume	15.32M
Volume	9,324,110

Perf Week	5.36%
Perf Month	6.22%
Perf Quarter	34.13%
Perf Half Y	-8.03%
Perf YTD	-4.99%
Perf Year	-29.44%
Perf 3Y	-38.43%
Perf 5Y	15.37%
Perf 10Y	82.38%
Recom	2.38
Target Price	48.86
Prev Close	48.07
Price	48.34
Change	0.56%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Jun-29-26 05:00AM	3 late-stage MASH drugs that could rival Rezdiffra (Pharma Voice)
Jun-26-26 12:47PM	How Micron aims to break through the risk cycle that has spooked investors for decades (MarketWatch)
Jun-25-26 11:26PM	HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most Voluminous Telehealth Partners (Stocktwits)
12:14AM	VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play (Stocktwits)
Jun-24-26 11:35AM	Millions of older Americans will soon have Medicare access to GLP-1s for weight loss. Here's what they need to know. (MarketWatch)
05:00AM	Loading…
05:00AM	Recent pharma exec shake-ups signal strategic shifts (Pharma Voice)
Jun-23-26 07:46PM	VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation (Stocktwits)
Jun-22-26 09:34AM	UPS invests $48 million in cold-chain healthcare logistics (Quartz) +6.23%
08:47AM	PwC Survey Finds 70% of GLP-1 Users Cutting Snack Spending (GuruFocus.com)
Jun-19-26 02:01PM	Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push (GuruFocus.com)
01:46PM	Novo Nordisk Rises as Foundation Launches EUR 60 Million Incubator (GuruFocus.com)
08:32AM	Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns (Proactive)
08:08AM	Novo Bets Bigger on Obesity Research (GuruFocus.com)
07:41AM	Stocks dip after US-Iran peace talks delay; yen hovers near 40-year lows (Reuters)
04:49AM	European stocks edge higher, helped by energy and healthcare (Reuters)
01:59PM	Loading…
Jun-18-26 01:59PM	Hims & Hers Rallies With a July FDA Decision Looming (GuruFocus.com)
06:58AM	Oral Wegovy Captures One-Third of Prescriptions as Adoption Continues to Accelerate (InvestorsHub)
Jun-17-26 04:46PM	HIMS Stock Gained Nearly 6% On Wednesday Barclays Sees Breakout Potential After Novo Partnership (Stocktwits)
03:41PM	J&J Has No Plans to Enter Obesity Drugs Market, CEO Says (Bloomberg)
03:33PM	J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030 (GuruFocus.com)
11:36AM	Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says (Investing.com)
08:08AM	Novo Nordisk hack: FulcrumSec claims $25M extortion attempt (Quartz)
Jun-16-26 02:52PM	Novo Nordisk to File Oral Wegovy in China (GuruFocus.com)
08:37AM	Novo Seeks China Approval for Wegovy Pill (GuruFocus.com)
04:49AM	Nasdaq, S&P 500 Futures Catch Breath Ahead Of First Warsh-Led Fed Decision: Why SPCX, TSLA, RKLB, BABA, NVO, HOOD, STI Are Keeping Traders Hooked (Stocktwits)
Jun-15-26 01:56PM	HIMS Stock Set To Test A Crucial Resistance Is Retail Expecting A Breakout? (Stocktwits)
Jun-14-26 04:00AM	Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they dont have college degrees, new study finds (Fortune)
Jun-12-26 10:37AM	UK gives Wegovy GLP-1 pill first European approval (Just Drinks)
07:55AM	Novo Nordisk comeback stirs as Wegovy pill wins UK approval (Pharmaceutical Technology)
Jun-11-26 02:24PM	NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News (Stocktwits)
12:22PM	Loading…
12:22PM	Employers Rethink GLP-1 Coverage (GuruFocus.com)
11:45AM	Novo Nordisk flags patient data breach from some clinical trials in cyberattack (Reuters)
Jun-09-26 03:50PM	Novo Nordisk puts AI at the centre of its clinical strategy (Pharmaceutical Technology)
03:48PM	Novo Wegovy Pill Tops 3M Prescriptions (GuruFocus.com)
02:42PM	Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before (CNBC TV)
02:40PM	Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy (CNBC TV)
Jun-08-26 05:32PM	LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZenecas Therapies In Diabetes Trials (Stocktwits)
01:26PM	Novo Drops 3.2% As CEO Eyes Longevity And Aesthetics (GuruFocus.com)
10:30AM	Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial (Quartz)
08:30AM	Novo Nordisk's weight loss pill is hitting 3 million U.S. prescriptions and most users had never tried one before (Quartz)
08:22AM	Novo Nordisk Wegovy pill reaches 3 million U.S. prescriptions (Quartz)
07:01AM	ADA 26: Lillys dominance, Pfizers foundational drug and Roches me-too option (BioPharma Dive)
06:42AM	Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO) (InvestorsHub)
06:16AM	Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug (MarketWatch)
05:44AM	Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. (Barrons.com)
04:58AM	3 potential takeover targets in obesity (Pharma Voice)
04:44AM	Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial (MarketWatch)
Jun-07-26 07:35PM	The Wegovy pill is still dominating the GLP-1 pill market (MarketWatch)
Jun-06-26 02:53PM	Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy. (MarketWatch)
10:04AM	Pfizer targets obesity market with monthly weight-loss injection data (Investing.com)
Jun-05-26 02:31PM	Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally (GuruFocus.com)
01:19PM	GLP-1 Sales Forecast Jumps To $150 Billion By 2030 (GuruFocus.com)
08:53AM	TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 Industry Leaders LLY, NVO To Remain Dominant (Stocktwits)
Jun-04-26 01:16PM	This Small-Cap Biotech Just Soared Over 160% What Is The Novo Nordisk Connection? (Stocktwits)
10:22AM	Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU) (InvestorsHub)
12:01AM	ASML Becomes Biggest Company in European History (The Daily Upside)
Jun-03-26 04:12PM	ASML Becomes Europe's Most Valuable Stock Ever (GuruFocus.com)
04:12PM	Denmark GDP Forecast Raised to 3.7% as Exports Power Ahead (GuruFocus.com)
12:07PM	Novo Nordisk is taking its Wegovy pill beyond the U.S. (GuruFocus.com)
09:19AM	Novo Nordisk launches Wegovy pill in UAE, its first global market (Quartz)
09:19AM	Novo Nordisk is taking its new weight loss pill global (Quartz)
06:21AM	Novo Nordisk Expands Wegovy Rollout with Launch of Weight-Loss Pill in UAE (NVO) (InvestorsHub)
04:40AM	Why Is Novo Nordisk Stock Climbing Premarket Today? (Stocktwits)
May-29-26 07:06PM	Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot (Barrons.com)
10:22AM	Lilly Reopens Zepbound Access For 10 Million US Patients (GuruFocus.com)
06:00AM	Eli Lilly's $1 trillion valuation cements its status as Wall Street's ultimate weight-loss play (Yahoo Finance)
May-28-26 06:14PM	Eli Lilly Jumps as CVS Expands Weight-Loss Drug Coverage (GuruFocus.com)
06:07PM	CVS Restores Coverage for Lilly's Zepbound (GuruFocus.com)
03:08PM	Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans (MarketWatch)
02:07PM	CVS will add these weight-loss options to drug plans (USA TODAY)
12:37PM	Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. (Barrons.com)
09:03AM	Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables (Proactive)
07:33AM	Small biotech firms quicker to 'latch onto' AI than big ones, says Tencent Healthcare President (Reuters)
07:30AM	CVS Caremark is reversing course on Eli Lilly's weight loss drugs, adding both its shot and new pill to coverage (Quartz)
07:20AM	CVS Caremark adds Zepbound and Foundayo to insurance coverage (Quartz)
07:09AM	CVS obesity drug deal puts Lilly on equal footing with Novo (BioPharma Dive)
06:49AM	CVS brings back coverage for Lilly's obesity drug Zepbound (Reuters)
04:48AM	LLY, NVO Stocks Led Mays GLP-1 Rally But This Smaller Differentiated Player Got A Bold 160% Upside Call (Stocktwits)
May-27-26 12:43AM	HIMS Stock Heads For Weekly Loss But Ex-Netflix CFO Is Buying The Dip Despite BofAs GLP-1 Warning (Stocktwits)
May-26-26 02:54PM	Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA (Proactive)
09:25AM	Novo Nordisk and Eli Lilly Just Delivered Potential Breakthrough for Cancer Patients (GuruFocus.com)
May-22-26 11:04AM	Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record (Proactive)
08:02AM	Lilly and Novo Weight-Loss Drugs Show Potential Cancer Benefits (GuruFocus.com)
02:24AM	HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry (Stocktwits)
May-21-26 02:41PM	Lilly Obesity Drug Shows 28% Weight Loss (GuruFocus.com)
02:09PM	Eli Lilly Obesity Drug Delivers Up to 28.3% Weight Loss (GuruFocus.com)
12:15PM	Canada and India now have generic Wegovy. Here's why the U.S. doesn't. (MarketWatch)
09:56AM	Eli Lilly's New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial (Barrons.com)
09:34AM	New weight-loss shot more powerful than old GLP-1s, Eli Lilly says (USA TODAY)
06:07AM	Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say (Reuters)
01:00AM	Live Longer and Better. Does Medicine's New Obsession Really Work? (Barrons.com)
May-20-26 02:14PM	Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth (GuruFocus.com)
May-18-26 01:30PM	Some people lose far more weight than others on GLP-1s like Wegovy. Here's why. (MarketWatch)
09:02AM	AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug (GuruFocus.com)
08:25AM	Novo Nordisk Eyes Global Push for Wegovy Pill (GuruFocus.com)
08:05AM	Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says (Proactive)
05:21AM	Race intensifies to lead next wave of obesity drugs as trial results loom (Pharma Voice)
May-13-26 07:37AM	Novo Nordisks high-dose Wegovy touts near 28% weight loss in early responders (Clinical Trials Arena)
May-12-26 01:01PM	Hims & Hers shares plunge after surprise loss and revenue miss (GuruFocus.com)
10:30AM	The $59B Quiet Shift Reshaping How Patients Access Care (PR Newswire)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Executive VPMr. Karsten Munk Knudsen

PresidentMr. Maziar Mike Doustdar B.A.

EVP of R&DDr. Martin Holst Lange

EVP of PeopleMs. Tania Sabroe

Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Novo Nordisk ADR

Upgrade your Finviz experience